Novo Nordisk's experimental weight loss pill, amycretin, has shown promising results in a Phase 1 clinical trial, demonstrating an average body weight reduction of up to 13% after three months.

Amycretin distinguishes itself by being an oral medication that targets both amylin and GLP-1 receptors, a dual-action mechanism not previously available in pill form.

Experts have raised concerns regarding the rapidity of weight loss, emphasizing the need for sustainable methods to maintain health and lean body mass.

The drug appears to be safe, with side effects primarily consisting of mild to moderate gastrointestinal issues, similar to those seen with other GLP-1 medications.

However, experts caution about the long-term implications of using GLP-1 medications, particularly in children and those with eating disorders.

Novo Nordisk has initiated Phase 2 trials of amycretin in individuals with Type 2 diabetes, further exploring its therapeutic potential.

In comparison, participants taking a placebo only experienced a modest weight loss of 1.1% during the same period.

Those on the highest dose of amycretin lost an average of 13.1% of their body weight, highlighting the drug's potential effectiveness.

This development aligns with Novo Nordisk's ongoing commitment to addressing obesity, reflecting a broader focus within the pharmaceutical industry on weight management solutions.

If future studies confirm these findings, amycretin could introduce competition in the obesity treatment market, potentially lowering treatment costs.

Further details regarding side effects and participant dropout rates are expected to be shared pending publication in a peer-reviewed journal.

Novo Nordisk's CEO has expressed optimism that amycretin could evolve into a 'best-in-class' treatment for obesity.